Osteologix Holdings (OLGXF) 0.0068 $OLGXF Osteoarthritis

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Osteologix Holdings (OLGXF) 0.0068 $OLGXF

Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 3.90 (-0.23), CBMG: 14.84 (-0.40), OCAT: 8.47 (+0.01), ZBH: 116.48 (-0.23), PFE: 34.22 (-0.53), LLY: 73.86 (-0.39), GSK: 40.33 (-0.24), GLPG: 51.37 (-0.89), AXSM: 6.34 (-0.61), OMER: 10.55 (-0.43), CANF: 2.62 (-0.16), AST: 2.97 (-0.06), AKTX: 14.61 (-0.19)

Bone Metastasis Pipeline Review, H1 2015
M2 - Thu Jun 11, 10:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tvrmb7/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Alethia Biotherapeutics Inc. - Amgen Inc. - Amura Holdings Ltd. - Bayer AG - ChemoCentryx, Inc. - Debiopharm International S.A. - Deciphera Pharmaceuticals, LLC - Digna Biotech, S.L. - Medivir AB - Merrion Pharmaceuticals Plc - Osteologix Holdings Plc. - R-Pharm - Sigma-Tau S.p.A. For more information visit http://www.researchandmarkets.com/research/tv...metastasis
CCXI: 4.75 (-0.05), AMGN: 149.62 (-2.68)

Post Menopausal Osteoporosis - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/kgcd25/post_menopausal) has announced the addition of the "Post Menopausal Osteoporosis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Post Menopausal Osteoporosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Post Menopausal Osteoporosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Post Menopausal Osteoporosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Merck & Co - Pfizer - Osteologix Holdings - Unigene Laboratories - Radius Health - Chronos Therapeutics - Amgen Astellas BioPharma - Paras Biopharmaceuticals Finland For more information visit http://www.researchandmarkets.com/research/kg...menopausal
RDUS: 36.04 (+0.11), MRK: 55.89 (-1.61), AMGN: 149.62 (-2.68)

Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 149.62 (-2.68), LLY: 73.86 (-0.39)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 354

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 298

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 292

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading

Top 5 Most Recently Viewed Articles

Zenarate Achieves Remarkable Growth, Securing Top Technology Honors

Updated Category News Views 231

Zenarate's Impressive Achievement in the Fast-Growing Tech Sector Zenarate, a leading platform focused on enhancing human and AI agent performance, has made waves in the tech industry with its exceptional ranking. With a remarkable growth of 496%, Zenarate has earned the prestigious recognition as the 165th fastest-growing company on the Deloitte Technology Fast 500™...

Continue Reading
GitLab Inc. Investors Encouraged to Participate in Class Action

Updated Category News Views 64

Important Class Action Opportunity for GitLab Inc. Investors GitLab Inc. shareholders are facing a critical moment, with a significant class action opportunity emerging due to recent events. Robbins Geller Rudman & Dowd LLP has made a vital announcement urging investors who bought GitLab securities during specific dates to come forward. This class action lawsuit, known as...

Continue Reading
Transforming $1000 into Significant Wealth with EME Investment

Updated Category News Views 261

Transform Your Investment Journey with EMCOR Group Investing wisely is a journey that can lead to fruitful rewards, especially when considering the historical performance of a stock. EMCOR Group (EME) is a fine example, having shown impressive growth over the past 15 years. If one were to invest $1000 in EME back then, they would be pleasantly surprised by today's...

Continue Reading
Brown & Brown, Inc. Declares Regular Quarterly Dividend Payment

Updated Category News Views 199

Brown & Brown, Inc. Dividends: Commitment to Shareholders Brown & Brown, Inc. (NYSE: BRO), an established insurance brokerage firm, recently made headlines with the announcement of a quarterly cash dividend of $0.15 per share. This decision was made public by the company's board of directors, illustrating their ongoing commitment to delivering value to their shareholders....

Continue Reading
OCS Finalizes Landmark Acquisition of EMCOR UK for Growth

Updated Category News Views 251

OCS Completes Acquisition of EMCOR UK OCS has officially completed its acquisition of EMCOR UK, marking a significant milestone in the facilities management sector. This strategic move follows the rigorous UK regulatory process, enabling OCS to merge with one of the largest hard services-led businesses in the region. The integration is expected to leverage the extensive...

Continue Reading